These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19583677)

  • 41. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19.
    Mihara K; Svensson US; Tybring G; Hai TN; Bertilsson L; Ashton M
    Fundam Clin Pharmacol; 1999; 13(6):671-5. PubMed ID: 10626755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.
    Tu JH; Hu DL; Dai LL; Sun Y; Fan L; Zhang M; Tan ZR; Chen Y; Li Z; Zhou HH
    Xenobiotica; 2010 Jun; 40(6):393-9. PubMed ID: 20350051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
    Miura M; Satoh S; Tada H; Saito M; Kagaya H; Inoue K; Sagae Y; Kanno S; Ishikawa M; Habuchi T; Suzuki T
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):605-13. PubMed ID: 17190370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.
    Ohlsson Rosenborg S; Mwinyi J; Andersson M; Baldwin RM; Pedersen RS; Sim SC; Bertilsson L; Ingelman-Sundberg M; Eliasson E
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1175-9. PubMed ID: 18654768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
    Ieiri I; Kubota T; Urae A; Kimura M; Wada Y; Mamiya K; Yoshioka S; Irie S; Amamoto T; Nakamura K; Nakano S; Higuchi S
    Clin Pharmacol Ther; 1996 Jun; 59(6):647-53. PubMed ID: 8681489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
    Ahmad L; Iqbal Z; Shah Y; Nazir S; Khan A; Khan MI; Khan A; Khuda F; Khan I
    Pak J Pharm Sci; 2018 Jul; 31(4):1363-1374. PubMed ID: 30033421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolism of omeprazole after two oral doses in children 1 to 9 months old.
    Hoyo-Vadillo C; Venturelli CR; González H; Romero E; Cervantes R; Mata N; Ortiz AC; Rincón V; Zarate F; Sosa C; Ramírez-Mayans J
    Proc West Pharmacol Soc; 2005; 48():108-9. PubMed ID: 16416673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.
    Shiohira H; Yasui-Furukori N; Yamada S; Tateishi T; Akamine Y; Uno T
    Pharm Res; 2012 Aug; 29(8):2310-6. PubMed ID: 22549736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.
    Kearns GL; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2010 Jun; 38(6):894-7. PubMed ID: 20223877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
    Kodaira C; Uchida S; Yamade M; Nishino M; Ikuma M; Namiki N; Sugimoto M; Watanabe H; Hishida A; Furuta T
    J Clin Pharmacol; 2012 Mar; 52(3):432-9. PubMed ID: 21415279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.
    Yang LJ; Fan L; Liu ZQ; Mao YM; Guo D; Liu LH; Tan ZR; Peng L; Han CT; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Jun; 65(6):601-8. PubMed ID: 19172254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.
    Zhou S; Xie R; Zhang X; He X; Huang J; Jungang Y; Liao M; Ding Y; Yang D; Liu Y; Zhang Q; Yang G; Liu F; Guan S; He Q; Lou H; Gong F; Meng X; Xiang Q; Zhao X; Cui Y
    Clin Transl Sci; 2022 Jun; 15(6):1439-1448. PubMed ID: 35235711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
    Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
    Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
    Hunfeld NG; Mathot RA; Touw DJ; van Schaik RH; Mulder PG; Franck PF; Kuipers EJ; Geus WP
    Br J Clin Pharmacol; 2008 May; 65(5):752-60. PubMed ID: 18241283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
    Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
    Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
    Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
    Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G; Böttiger Y; Widén J; Bertilsson L
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.